{
    "clinical_study": {
        "@rank": "143022", 
        "acronym": "guardian\u2122 5", 
        "arm_group": {
            "arm_group_label": "All patients"
        }, 
        "brief_summary": {
            "textblock": "This study is conducted in Europe, and North and South America. The aim of this study is to\n      provide additional documentation of the immunogenicity, and obtain additional clinical data,\n      of turoctocog alfa in the setting of normal clinical practise in patients previously treated\n      with a factor VIII agent (FVIII) and na\u00efve to turoctocog alfa."
        }, 
        "brief_title": "Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Congenital Bleeding Disorder", 
            "Haemophilia A"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemophilia A", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any study-related activities. Study-related\n             activities are any procedure related to recording of data according to the protocol\n\n          -  Previously FVIII treated (above 150 exposure days) male patients with the diagnosis\n             of severe and moderately severe haemophilia A (FVIII below or equal to 2%)\n\n          -  The decision to initiate treatment with commercially available turoctocog alfa has\n             been made by the patient/parent and the patient's treating physician before and\n             independently from the decision to include the patient in this study\n\n          -  No previous exposure to turoctocog alfa\n\n          -  No clinical suspicion of FVIII inhibitors\n\n          -  Availability of an FVIII inhibitor test obtained not more than four weeks prior to\n             first dosing with turoctocog alfa\n\n        Exclusion Criteria:\n\n          -  Contraindications for use according to the approved product information text (US\n             Package insert (PI), European Summary of Product Characteristics (SmPC), or\n             corresponding local prescribing information)\n\n          -  Treatment with any investigational drug within 30 days prior to enrolment into the\n             study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Previously FVIII treated (more than 150 exposure days) and turoctocog alfa na\u00efve patients\n        with severe and moderately severe haemophilia A with FVIII below or equal to 2%."
            }
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035384", 
            "org_study_id": "NN7008-3553", 
            "secondary_id": [
                "U1111-1126-0353", 
                "ENCEPP/SDPP/5501"
            ]
        }, 
        "intervention": {
            "arm_group_label": "All patients", 
            "description": "Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.", 
            "intervention_name": "turoctocog alfa", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multi-centre Non-interventional Study of Safety and Efficacy of Turoctocog Alfa (rFVIII) During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (FVIII =<2%)", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Austria: Agency for Health and Food Safety", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Finland: Finnish Medicines Agency", 
                "France: Ministry of Health", 
                "Germany: Paul-Ehrlich-Institut", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Norway: Norwegian Medicines Agency", 
                "Sweden: Medical Products Agency", 
                "Switzerland: Swissmedic", 
                "United States: Food and Drug Administration", 
                "Denmark: Danish Medicines Agency", 
                "Italy: The Italian Medicines Agency", 
                "Portugal: National Pharmacy and Medicines Institute", 
                "Slovakia: State Institute for Drug Control", 
                "Slovenia: Agency for Medicinal Products - Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence rate of FVIII inhibitors (at least 0.6 Bethesda Units (BU)/mL for central laboratory analyses, or above the specific local laboratory reference range) represented as the percentage of patients developing inhibitors", 
            "safety_issue": "No", 
            "time_frame": "Within approximately 4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035384"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of adverse reactions reported", 
                "safety_issue": "No", 
                "time_frame": "During approximately 4 years"
            }, 
            {
                "measure": "Number of serious adverse reactions reported", 
                "safety_issue": "No", 
                "time_frame": "During approximately 4 years"
            }, 
            {
                "measure": "Haemostatic effect of turoctocog alfa in the treatment of bleeds as assessed by the patient or the physician according to a predefined four point scale: Excellent, Good, Moderate, or None", 
                "safety_issue": "No", 
                "time_frame": "Within approximately 4 years"
            }, 
            {
                "measure": "Haemostatic effect of turoctocog alfa during surgical procedures as assessed by an evaluation according to a predefined four point scale: Excellent, Good, Moderate, or None", 
                "safety_issue": "No", 
                "time_frame": "Within approximately 4 years"
            }, 
            {
                "measure": "Annualised bleeding rate for patients using turoctocog alfa for preventive treatment", 
                "safety_issue": "No", 
                "time_frame": "Within approximately 4 years"
            }, 
            {
                "measure": "Annualised bleeding rate for patients using turoctocog alfa for on-demand treatment", 
                "safety_issue": "No", 
                "time_frame": "Within approximately 4 years"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}